Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame(TM) Study of Iluvien(R) in Patients With Diabetic Macul

Biopharmaceutical company Alimera Sciences has announced that positive new data from its completed FAME Study fo Iluvien were pr... [more]

View complete Press Release article